Bayer Pharma and Ventana enter agreement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

VENTANA MEDICAL SYSTEMS INC. has entered into a multi-year agreement with Bayer Pharma AG to develop companion diagnostics with a focus on immunohistochemistry, across Bayer’s portfolio of targeted therapy projects.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

The White House Office of Management and Budget has published a “Regulation for Federal Financial Assistance,” a proposed rule that seeks to fundamentally redraw the ground rules for all federally funded research. On the other side are America’s scientists who aren’t just crying foul—they are readying for a political fight.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login